References
- Ngugi AK, Bottomley C, Kleinschmidt I, et al. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia. 2010;51(5):883–890.
- Velisek L, Nebieridze N, Chachua T, et al. Anti-seizure medications and estradiol for neuroprotection in epilepsy: the 2013 update. RPCN. 2013;8(1):24–41.
- Wang W, Wu J, Li S, et al. Sodium valproate for epilepsy in rural China: an efficacy and safety assessment in primary care. Epilepsy Res. 2012;102(3):201–205.
- Stephen LJ, Sills GJ, Leach JP, et al. Sodium valproate versus lamotrigine: a randomised comparison of efficacy, tolerability and effects on circulating androgenic hormones in newly diagnosed epilepsy. Epilepsy Res. 2007;75(2-3):122–129.
- Marson AG, Appleton R, Baker GA, et al. A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial. Health Technol Assess. 2007;11(37):iii–iv, ix–x, 1–134.
- Wilder BJ, Rangel RJ. Review of valproate monotherapy in the treatment of generalized tonic-clonic seizures. Am J Med. 1988;84(1):7–13.
- Ibi D, Fujiki Y, Koide N, et al. Paternal valproic acid exposure in mice triggers behavioral alterations in offspring. Neurotoxicol Teratol. 2019;76:106837.
- Bialer M. Why are antiepileptic drugs used for nonepileptic conditions? Epilepsia. 2012;53 (Suppl 7):26–33.
- Safar MM, Abdallah DM, Arafa NM, et al. Magnesium supplementation enhances the anticonvulsant potential of valproate in pentylenetetrazol-treated rats. Brain Res. 2010;1334:58–64.
- Toledo M, Beale R, Evans JS, et al. Long-term retention rates for antiepileptic drugs: A review of long-term extension studies and comparison with brivaracetam. Epilepsy Res. 2017;138:53–61.
- Kwok CS, Johnson EL, Krauss GL. Comparing safety and efficacy of “third-generation” antiepileptic drugs: long-term extension and post-marketing treatment. CNS Drugs. 2017;31(11):959–974.
- Penovich PE, Gruenthal M. From patterns to patients: what can we tell people with newly diagnosed epilepsy? Neurology. 2012;78(20):1542–1543.
- Duseja A, Singh SP, Saraswat VA, et al. Non-alcoholic fatty liver disease and metabolic syndrome-position paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. J Clin Exp Hepatol. 2015;5(1):51–68.
- Belcastro V, D’Egidio C, Striano P, et al. Metabolic and endocrine effects of valproic acid chronic treatment. Epilepsy Res. 2013;107(1-2):1–8.
- Toledo M, Fonseca E, Olive M, et al. Long-term retention rates of antiepileptic drugs used in acute seizures. Seizure. 2018;61:78–82.
- Brodie MJ, Barry SJ, Bamagous GA, et al. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012;78(20):1548–1554.
- Villanueva V, Lopez FJ, Serratosa JM, et al. Control of seizures in different stages of partial epilepsy: LACO-EXP, a Spanish retrospective study of lacosamide. Epilepsy Behav. 2013;29(2):349–356.
- Yuen AW, Sander JW. Can magnesium supplementation reduce seizures in people with epilepsy? A hypothesis. Epilepsy Res. 2012;100(1–2):152–156.
- Lee SW, Chung SS. A review of the effects of vitamins and other dietary supplements on seizure activity. Epilepsy Behav. 2010;18(3):139–150.
- Dharnidharka VR, Carney PR. Isolated idiopathic hypomagnesemia presenting as aphasia and seizures. Pediatr Neurol. 2005;33(1):61–65.
- Gathwala G. Neuronal protection with magnesium. Indian J Pediatr. 2001;68(5):417–419.
- Czeh G, Somjen GG. Changes in extracellular calcium and magnesium and synaptic transmission in isolated mouse spinal cord. Brain Res. 1989;486(2):274–285.
- Yang Y, Tian X, Xu D, et al. GPR40 modulates epileptic seizure and NMDA receptor function. Sci Adv. 2018;4(10):eaau2357.
- Shangguan Y, Xu X, Ganbat B, et al. CNTNAP4 impacts epilepsy through GABAA receptors regulation: evidence from temporal lobe epilepsy patients and mouse models. Cereb Cortex. 2018;28(10):3491–3504.
- Xu X, Shangguan Y, Lu S, et al. Tubulin beta-III modulates seizure activity in epilepsy. J Pathol. 2017;242(3):297–308.
- Xu X, Hu Y, Xiong Y, et al. Association of microtubule dynamics with chronic epilepsy. Mol Neurobiol. 2016;53(7):5013–5024.
- Xu X, Yang X, Xiong Y, et al. Increased expression of receptor for activated C kinase 1 in temporal lobe epilepsy. J Neurochem. 2015;133(1):134–143.
- Cao HY, Jiang YW, Liu ZW, et al. Effect of recurrent epileptiform discharges induced by magnesium-free treatment on developing cortical neurons in vitro. Brain Res Dev Brain Res. 2003;142(1):1–6.
- Long S, Romani AM. Role of cellular magnesium in human diseases. Austin J Nutr Food Sci. 2014;2(10):1051.
- Zeiler FA, Matuszczak M, Teitelbaum J, et al. Magnesium sulfate for non-eclamptic status epilepticus. Seizure. 2015;32:100–108.
- Doyle LW, Crowther CA, Middleton P, et al. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev. 2009;1(1):CD004661.
- Balagura G, Iapadre G, Verrotti A, et al. Moving beyond sodium valproate: choosing the right anti-epileptic drug in children. Expert Opin Pharmacother. 2019;20(12):1449–1456.
- Brodie MJ, Stephen LJ. Prospective audit with adjunctive perampanel: preliminary observations in focal epilepsy. Epilepsy Behav. 2016;54:100–103.